CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective StudiesGOETZ, M. P; INGLE, J. N.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 2, pp 141-144, issn 0009-9236, 4 p.Article

The Scientific Basis of Body Surface Area-Based DosingCHATELUT, E; PUISSET, F.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 4, pp 359-361, issn 0009-9236, 3 p.Article

Antiretroviral Therapy-Induced Mitochondrial Toxicity: Potential Mechanisms Beyond Polymerase-γ InhibitionSELVARAJ, S; GHEBREMICHAEL, M; CHENG, Y.-C et al.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 1, pp 110-120, issn 0009-9236, 11 p.Article

Characterization of Statin Dose Response in Electronic Medical RecordsWEI, W.-Q; FENG, Q; NICKERSON, D. A et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 3, pp 331-338, issn 0009-9236, 8 p.Article

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α-Based RegimensMUIR, A. J; GONG, L; JOHNSON, S. G et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 2, pp 141-146, issn 0009-9236, 6 p.Article

Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial FibrillationPINK, J; PIRMOHAMED, M; LANE, S et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 2, pp 199-207, issn 0009-9236, 9 p.Article

High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the ParadigmTUTEJA, S; RADER, D. J.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 1, pp 48-56, issn 0009-9236, 9 p.Article

PBPK Model Describes the Effects of Comedication and Genetic Polymorphism on Systemic Exposure of DrugsThat Undergo Multiple Clearance PathwaysVIEIRA, Md L. T; KIM, M.-J; APPARAJU, S et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 5, pp 550-557, issn 0009-9236, 8 p.Article

Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next-Generation SequencingGUCHELAAR, H.-J; GELDERBLOM, H; VAN DER STRAATEN, T et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 4, pp 383-385, issn 0009-9236, 3 p.Article

Preserving Learned Immunosuppressive Placebo Response: Perspectives for Clinical ApplicationALBRING, A; WENDT, L; BENSON, S et al.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 2, pp 247-255, issn 0009-9236, 9 p.Article

Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in JapanUENO, T; ASAHINA, Y; TANAKA, A et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 5, pp 533-541, issn 0009-9236, 9 p.Article

The Biotechnology Innovation Machine: A Source of Intelligent Biopharmaceuticals for the Pharma Industry—Mapping Biotechnology's SuccessEVENS, R. P; KAITIN, K. I.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 5, pp 528-532, issn 0009-9236, 5 p.Article

A Forensic Analysis of Drug Targets From 2000 Through 2012MUNOS, B.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 3, pp 407-411, issn 0009-9236, 5 p.Article

Biomarkers for Smoking CessationBOUGH, K. J; LERMAN, C; GREEN, C et al.Clinical pharmacology and therapeutics. 2013, Vol 93, Num 6, pp 526-538, issn 0009-9236, 13 p.Article

Building a New Biomedical Ecosystem: Pfizer's Centers for Therapeutic InnovationPATEL, A. C; COYLE, A. J.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 3, pp 314-316, issn 0009-9236, 3 p.Article

CYP2A6 Genotype but not Age Determines Cotinine Half-Life in Infants and ChildrenDEMPSEY, D. A; SAMBOL, N. C; JACOB, P et al.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 3, pp 400-406, issn 0009-9236, 7 p.Article

Challenges in the Pharmacogenomic Annotation of Whole GenomesALTMAN, R. B; WHIRL-CARRILLO, M; KLEIN, T. E et al.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 2, pp 211-213, issn 0009-9236, 3 p.Article

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine DosingLECKBAND, S. G; KELSOE, J. R; DUNNENBERGER, H. M et al.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 3, pp 324-328, issn 0009-9236, 5 p.Article

Cometabolism of Microbes and Host: Implications for Drug Metabolism and Drug-Induced ToxicityLI, H; JIA, W.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 5, pp 574-581, issn 0009-9236, 8 p.Article

Computational Drug Repositioning: From Data to TherapeuticsHURLE, M. R; YANG, L; XIE, Q et al.Clinical pharmacology and therapeutics. 2013, Vol 93, Num 4, pp 335-341, issn 0009-9236, 7 p.Article

Computational Prospecting for Drug-Transporter Interactions : Transporters in Drug Development and Clinical PharmacologyMATSSON, P; ARTURSSON, P.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 1, pp 30-32, issn 0009-9236, 3 p.Article

Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium : Transporters in Drug Development and Clinical PharmacologyHILLGREN, K. M; KEPPLER, D; ZUR, A. A et al.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 1, pp 52-63, issn 0009-9236, 12 p.Article

First-Time-in-Human Study With GSK249320, a Myelin-Associated Glycoprotein Inhibitor, in Healthy VolunteersABILA, B; CUNNINGHAM, E; SIMEONI, M et al.Clinical pharmacology and therapeutics. 2013, Vol 93, Num 2, pp 163-169, issn 0009-9236, 7 p.Article

Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12VATER, A; SAHLMANN, J; VONHOFF, S et al.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 1, pp 150-157, issn 0009-9236, 8 p.Article

Intracellular Drug ConcentrationsDOLLERY, C. T.Clinical pharmacology and therapeutics. 2013, Vol 93, Num 3, pp 263-266, issn 0009-9236, 4 p.Article